PURPOSE: To reduce adverse effects of a selective 2-sympathomimetic bronchodilator useful for curing obstructive or inflammatory air duct diseases especially asthma and improve safety for uses in high doses or long periods. CONSTITUTION: A medicinal composition capable of avoiding improving or controlling occurrence of adverse effects harmful to the air duct especially turning to the worse of states of basic diseases and withdrawing or reducing of pulmonary functions by blending a selective 2-sy...

Products contg. as active substances azelastin (I) and theophylline or azelastin and one or more beta-mimetics or salts of these cpds. with physiologically harmless acids as a combination preparation for simultaneous separate administration are new. The products pref. contain 0.2-10000 wt. parts theophylline or 0.0001-1000 wt. parts beta-mimetic per wt. part azelastin. Dosage units pref. generally contain 0.1-50mg (pref. 0.2-20mg) azelastin and 10-1000mg (pref. 80-600mg) theophylline or 0.005-20...

PURPOSE: A percutaneous absorption pharmaceutical for external use obtained by using a sympathomimetic .beta.-receptor agent (bronchodilator) and an animal or vegetable oil or organic acid ester or both which are liquid at a specific temperature or below together and having improved percutaneous absorbability of the above-mentioned drug.CONSTITUTION: A percutaneous absorption pharmaeutical obtained by incorporating a sympathomimetic .beta.-receptor agent clinically and widely used as a bronchodi...

1487535 Compositions containing pyridoquinolines IMPERIAL CHEMICAL INDUSTRIES Ltd 15 April 1976 [19 May 1975] 21291/75 Heading A5B [Also in Division C2] Therapeutic compositions comprise compounds of formulae: wherein R' and R2 are different C 1-6 alkyl groups and benzene ring B may be substituted by C 1-6 alkyl C 1-6 alkoxy or/and halogen. They may be administered orally by inhalation or intravenously to treat intrinsic (non-allergic) asthma or a disease or syndrome initiated by antigen-anti...

1486869 Compositions containing pyridoquinolines IMPERIAL CHEMICAL INDUSTRIES Ltd 21 April 1976 [19 May 1975] 21290/75 Heading A5B [Also in Division C2] Theropeutic compositions comprise compounds of formulae wherein R1 is H or the same as R2; R2 is CH 2 R CHMeR or CHEtR R being CN C 2-4 alkanoyl benzoyl C 2-6 alkanolyloxy (C 1-5 - alkoxy) carbonyl Ph-(C 1-3 alkoxy) carbonyl or C 3-7 -(dialkylcarbamoyl); and benzene ring B may be substituted by C 1-6 alkyl C 1-6 alkoxy or/and halogen. They...

Novel compounds are disclosed having useful activity as bronchodilators of improved longevity of action and reduced incidence of side effects. These compounds are described by the formula: ##STR1## wherein R.sub.1 is a member of the class consisting of tertiary butyl and cyclobutyl and R.sub.2 is a hydrogen or 2 to 5 carbon atom acyl radical and pharmaceutically acceptable salts thereof. The activity of these compounds is compared to previously known bronchodilators such as 1-(3\' 5\'-dihydroxyp...

1486869 Compositions containing pyridoquinolines IMPERIAL CHEMICAL INDUSTRIES Ltd 21 April 1976 [19 May 1975] 21290/75 Heading A5B [Also in Division C2] Theropeutic compositions comprise compounds of formulae wherein R1 is H or the same as R2; R2 is CH 2 R CHMeR or CHEtR R being CN C 2-4 alkanoyl benzoyl C 2-6 alkanolyloxy (C 1-5 - alkoxy) carbonyl Ph-(C 1-3 alkoxy) carbonyl or C 3-7 -(dialkylcarbamoyl); and benzene ring B may be substituted by C 1-6 alkyl C 1-6 alkoxy or/and halogen.They ...

1487535 Compositions containing pyridoquinolines IMPERIAL CHEMICAL INDUSTRIES Ltd 15 April 1976 [19 May 1975] 21291/75 Heading A5B [Also in Division C2] Therapeutic compositions comprise compounds of formulae: wherein R' and R2 are different C 1-6 alkyl groups and benzene ring B may be substituted by C 1-6 alkyl C 1-6 alkoxy or/and halogen.They may be administered orally by inhalation or intravenously to treat intrinsic (non-allergic) asthma or a disease or syndrome initiated by antigen-antib...

Novel compounds are disclosed having useful activity as bronchodilators of improved longevity of action and reduced incidence of side effects. These compounds are described by the formula: ##EQU1## wherein R.sub.1 is a member of the class consisting of tertiary butyl and cyclobutyl and R.sub.2 is a hydrogen or 2 to 5 carbon atom acyl radical and pharmaceutically acceptable salts thereof. The activity of these compounds is compared to previously known bronchodilators such as 1-(3\' 5\'-dihydroxyp...

1414621 Antiallergic medicines WELLCOME FOUNDATION LTD 8 Dec 1972 [8 Sept 1971 24 Feb 1972 (3) 29 March 1972 1 Aug 1972 29 Aug 1972 (3)] 41852/71 8608/72 8609/72 8610/72 14909/72 35818/72 39939/72 39940/72 40079/72 Heading A5B [Also in Divisions C2 and C5] Therapeutic compositions having anti-allergic activity comprise (subject to disclaimer) compounds of formula wherein Z1 is COX X being OH (or a salt thereof) O-C 1-6 -alkyl or NA 2 (optionally C 1-6 alkyl substituted); Z3 is a bond CO O or N...